Dr. Choueiri discusses the significance of the FDA approval of pembrolizumab as adjuvant therapy in renal cell carcinoma and key data from the pivotal phase 3 KEYNOTE-564 trial.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
